![]() The method of claim 16, wherein the condition is selected from the group consisting of brain tumor, astrocytomas, glioblastoma, glioma, subependynoma, craniopharyngioma, arterio-venous malformations, ischemic events, multiple sclerosis, head injury, brain surgery, paraneoplastic syndromes, Neimann-Pick type C disease, and encephalitis.ġ8. The method of claim 1, wherein the cataplexy is secondary to a condition that lowers hypocretin levels in the subject.ġ7. The method of claim 1, wherein the cataplexy is associated with narcolepsy.ġ6. The method of claim 12, wherein the compound of Formula Ib predominates to the extent of about 98% or greater.ġ5. The method of claim 12, wherein the compound of Formula Ib predominates to the extent of about 90% or greater.ġ4. The method of claim 4, wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates: or a pharmaceutically acceptable salt or ester thereof.ġ3. The method of claim 7, wherein the enantiomer of Formula Ia predominates to the extent of about 98% or greater.ġ2. The method of claim 7, wherein the enantiomer of Formula Ia predominates to the extent of about 90% or greater.ġ1. The method of claim 7, wherein the enantiomer of Formula Ia is the (S) or (L) enantiomer.ġ0. The method of claim 7, wherein the enantiomer of Formula Ia is the (R) or (D) enantiomer.ĩ. The method of claim 4, wherein the enantiomer of Formula I is an enantiomer of Formula Ia: or a pharmaceutically acceptable salt or ester thereof.Ĩ. ![]() The method of claim 4, wherein the enantiomer of Formula I predominates to the extent of about 98% or greater.ħ. The method of claim 4, wherein the enantiomer of Formula I predominates to the extent of about 90% or greater.Ħ. ![]() The method of claim 1, wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.ĥ. The method of claim 1, wherein R 1 and R 2 are hydrogen and x=0.Ĥ. A method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3 R 1 and R 2 are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms or R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.ģ. Methods and Apparatus for Passive Reduction of Nosocomial Infections in Clinical Settings, and Fabrics, Yarns, and Filaments for Use in Connection Therewithġ. Use of Inhibitors of the Renin-Angiotensin System Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin Methods for supporting metabolism and transportation of glucose and carbohydrates into muscle Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers. Levothyroxine compositions having unique Tmax propertiesĭIVIDABLE GALENICAL FORM ALLOWING MODIFIED RELEASE OF THE ACTIVE INGREDIENT Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |